[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631784":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":63,"collaborators":21,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":21,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":21,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":88,"whyStopped":21,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Camrelizumab, Chemotherapy and Ivarmacitinib","EXPERIMENTAL","The preoperative neoadjuvant therapy consists of 3 cycles, each with a duration of 21 days. Ivarmacitinib tablets are administered orally at a dosage of 4 mg daily during the first and second cycles, but are omitted during the third cycle. Radical surgery is scheduled to occur between 4 to 8 weeks after the final dose of the neoadjuvant therapy. The requirement for postoperative radiotherapy is evaluated based on the patient's clinical condition and pathological stage. Camrelizumab maintenance therapy may be extended for up to 1 year. Throughout the study, patients are monitored until the occurrence of disease progression, withdrawal of informed consent, loss to follow-up, or death.",[13,14,15],"Combination Product: Camrelizumab, Chemotherapy and Ivarmacitinib","Procedure: Esophagectomy","Other: Sample",[17,22,27],{"type":18,"name":9,"description":19,"armGroupLabels":20,"otherNames":21},"COMBINATION_PRODUCT","The treatment regimen includes the administration of Camrelizumab at a dose of 200 mg, Paclitaxel (albumin-bound) at 260 mg\u002Fm², and Carboplatin with an area under the curve (AUC) of 5. These medications are administered every 3 weeks for a total of 3 cycles. Additionally, Ivarmacitinib tablets are administered orally at a dosage of 4 mg daily during the first and second cycles, but are omitted during the third cycle, totaling 42 days of administration.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"PROCEDURE","Esophagectomy","Prior to each surgical procedure, the department engaged in comprehensive discussions to determine and establish the most appropriate course of action. Depending on the tumor location, a minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two-field extensive lymphadenectomies, was performed. The resection length was required to be at least 5 cm from the tumor origin, as determined by pre-chemotherapy endoscopy. These surgeries were conducted by surgeons with extensive experience. Minimally invasive esophagectomy could be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or through an open approach, as deemed appropriate by the surgeon.",[9],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":21},"Sample","Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and during surgery.",[9],[32],{"name":33,"affiliation":34,"role":35},"Jianan Wang","2nd Affiliated Hospital, School of Medicine, Zhejiang University","STUDY_CHAIR",[37],{"name":38,"role":39,"phone":40,"phoneExt":21,"email":41},"Zixiang Ｗu, M.D","CONTACT","+8615268156132","zixiang0717@zju.edu.cn",[43],{"facility":34,"status":21,"city":44,"state":45,"zip":46,"country":45,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hangzhou","China","310009","CN",{"type":49,"coordinates":50},"Point",[51,52],120.16142,30.29365,{"lat":52,"lon":51},[55,59],{"name":56,"role":39,"phone":57,"phoneExt":21,"email":58},"Ming Wu, M.D","+8613757118715","iwuming22@zju.edu.cn",{"name":60,"role":39,"phone":61,"phoneExt":21,"email":62},"Hong Shen, M.D","+8613362891320","shenhong0023@zju.edu.cn",{"type":64,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100631784","phase-2-camrelizumab-chemotherapy-and-ivarmacitinib-in-patients-with-resectable-esophageal-squamous-cell-carcinoma-100631784",false,"NCT07505186","Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma","A Prospective, Single-arm, Single-center, Exploratory Study of the Safety and Efficacy of the Combination of Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. signed informed consent;\n2. patients age 18 to 75 years old\n3. primary resectable, histologically confirmed esophageal squamous cell cancer;\n4. Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).\n5. ECOG PS 0-1.\n6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist．\n\nExclusion Criteria:\n\n1. with significant cardiovascular disease;\n2. current treatment with anti-viral therapy or HBV;\n3. Female patients who are pregnant or lactating;\n4. history of malignancy within 5 years prior to screening;\n5. active or history of autoimmune disease or immune deficiency;\n6. signs of distant metastases.","ALL","18 Years","75 Years",{"count":76,"type":77},45,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","In the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have been suboptimal. Immune checkpoint inhibitors (ICIs) have shown potential in enhancing the immune system's capacity to target and eliminate cancer cells. Evidence suggests that the concurrent administration of JAK inhibitors with ICIs may improve anti-cancer efficacy, increase patient response rates, and prolong progression-free survival compared to ICIs alone. This prospective, exploratory study aims to assess the efficacy of combining camrelizumab, chemotherapy, and Ivarmacitinib in neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma, with the objective of broadening therapeutic options for this malignancy.",[83,84],"Esophageal Squamous Cell Carcinoma","Neoadjuvant Therapy",[86,87],"Camrelizumab","Ivarmacitinib","NOT_YET_RECRUITING","2026-03-26",{"date":91,"type":92},"2026-04-01","ACTUAL",{"date":94,"type":77},"2026-05-01",{"date":96,"type":77},"2033-12-31",{"name":5,"class":6},1]